Hentschke P, Hägglund H, Mattsson J, Carlens S, Lönnqvist B, Ljungman P, Aschan J, Fredrikson S, Ringdén O
Centre for Allogeneic Stem Cell Transplantation, Huddinge Hospital, Stockholm, Sweden.
Bone Marrow Transplant. 1999 Nov;24(9):1033-5. doi: 10.1038/sj.bmt.1702018.
Between 1990 and 1996, three patients (1.1%), all with CML, among 272 patients with haematological malignancies, developed bilateral subdural haematomas (SDH) after treatment with i.t. MTX before HSCT in our unit. Since October 1996, we have given i.t. MTX only to patients at increased risk of CNS leukaemia such as ALL and AML M4 or M5. We suggest that intrathecal treatment before HSCT should only be given to patients at increased risk of CNS leukaemia.
1990年至1996年间,在我们科室接受造血干细胞移植(HSCT)前鞘内注射甲氨蝶呤(MTX)治疗的272例血液系统恶性肿瘤患者中,有3例(1.1%)均为慢性粒细胞白血病(CML)患者,发生了双侧硬膜下血肿(SDH)。自1996年10月以来,我们仅对中枢神经系统白血病(CNS白血病)风险增加的患者,如急性淋巴细胞白血病(ALL)、急性髓系白血病M4或M5患者给予鞘内注射MTX。我们建议,HSCT前的鞘内治疗应仅用于CNS白血病风险增加的患者。